Season 2, Episode 8 - Treatment of HBV-HDV coinfection in the era of entry inhibition
In this episode of EASL studio, learn about the clinical management and treatment of hepatitis delta infection in the era of emerging treatments.
- What does the clinical management of Hepatitis Delta infection look like in the era of emerging new treatments?
- What is the prevalence of anti-HDV and HDV RNA positivity?
- How do you manage HBV-HDV co-infected patients?
Related episode – Interview with Stephan Urban – From bench to bedside: Process of developing the first HBV/HDV entry inhibitor
This project has been made possible with the provision of a financial grant from Gilead Sciences Europe Ltd.
EASL has received no input from Gilead with regards to the content of this programme.
Speakers
Magdalena Filipowicz Sinnreich
PD. Dr. med. Dr. phil. Magdalena Filipowicz Sinnreich is the head of the Liver Immunology Laboratory at the Department of Biomedicine of the University Hospital in Basel, Switzerland, and the head of the liver service at the Gastroenterology Department of the Kantonsspital Baselland, a hospital affiliated with the University of Basel.
Read more
She is a lecturer in hepatology and basic science at the University of Basel. She has published in numerous peer reviewed journals on Hepatitis C virus infection and liver immunology. She is a recipient of the Pfizer Research Prize in Switzerland, the Senior Hepatology Prize of the Swiss Society of Gastroenterology, and the EASL Sheila Sherlock Postdoctoral Fellowship award. She is an advocate for women in science and women in hepatology.
Pietro Lampertico
Professor Pietro Lampertico is Full Professor in the Gastroenterology, Director of the Gastroenterology and Hepatology Division. He is also head of the “A. M. e A. Migliavacca” Center for Liver Disease at the Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Read more
In the Gastroenterology Unit, Professor Lampertico is primarily involved in the clinical management of chronic viral hepatitis outpatients, particularly those with CHB and CHD.
His research interests include the treatment of patients with chronic hepatitis/cirrhosis due to HBV and HDV, the long-term outcome of cirrhotic patients undergoing antiviral treatment, and the diagnosis and management of antiviral resistance to oral nucleos(t)ide analogues.
Heiner Wedemeyer
Heiner Wedemeyer is Professor and Chairman of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School since April 1, 2020.
Read more
His long-term research interest is in liver diseases with special focus on viral hepatitis, liver transplantation and hepatocellular carcinoma. He has been principal investigator in numerous clinical trials, focusing on antiviral therapy and immunotherapy of viral hepatitis B, C, D and E.
Heiner Wedemeyer is member of several scientific organizations and was Secretary General of the European Association for the Study of the Liver from 2009 to 2011.
